Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA, Moderna appear aligned on mRNA flu shot heading into adcomm
  • Regulatory

FDA, Moderna appear aligned on mRNA flu shot heading into adcomm

BioSpace

The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna's seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in Febru

Infectious Disease

Read full story

pharminent June 16, 2026

BioSpace

The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna’s seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in Febru

Infectious Disease

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: German said to be backtracking on pharma rebate changes
Next: EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

Related Stories

  • Regulatory

Outlook Therapeutics Secures FDA Approval for LYTENAVA

pharminent July 31, 2026
  • Regulatory

Outlook finally claims FDA approval for AMD drug

pharminent July 27, 2026
  • Regulatory

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

pharminent July 27, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.